Abbott confirms success of Xience V

Abbott Vascular has confirmed that results from its latest study show Xience V can reduce vessel re-narrowing in people with coronary artery disease when compared to Taxus.

The study, Spirit III, was published in the Journal of the American Medical Association and has found that the use of Xience V Everolimus Eluting Coronary Stent System can lead to a 50 per cent reduction in vessel re-narrowing at eight months, as well as non-inferior rates of target vessel failure at nine months.

Further to this, there is a 42 per cent reduction in major adverse cardiac events after one year, when compared to use of the Taxus Paclitaxel-Eluting Coronary Stent System.

“Spirit III is the first large-scale clinical trial to show that patients have a lower risk of experiencing a heart attack, cardiac death or re-treatment when treated with a new stent, Xience V,” said the principal investigator in the trial, Dr Gregg W Stone.

He added that the Xience V represents a key new advance in improving the lives of patients suffering from coronary artery disease.

Abbott Vascular claims it has a range of products that are internationally recognized for their effectiveness and safety for the treatment of vascular diseases.